Good
Mostly Aligned
Patient Risk:
Low
Summary
Most safety-related claims align with the provided label excerpts (IL-17A MOA and live vaccine avoidance). However, several statements concerning vaccine timing and external recommendations (CDC/experts) are not supported by the supplied FDA labeling excerpts, and one claim about adverse reaction risk for live vaccines is not supported by the label text provided.
Category Scores
Accurate Statements
Cosentyx works by blocking the action of interleukin-17A.
Section 12.1 Mechanism of Action: selectively binds to IL-17A and inhibits its interaction with the IL-17 receptor.
The manufacturer of Cosentyx (Novartis) states that patients should not receive live vaccines while taking Cosentyx.
Section 5.7 Immunizations: COSENTYX may alter immune response to live vaccines; Avoid use of live vaccines in patients treated with COSENTYX.
Cosentyx may make it more difficult for the body to respond to live vaccines.
Section 5.7 Immunizations: COSENTYX may alter a patient's immune response to live vaccines.
Cosentyx may suppress the immune system, making it more difficult for the body to respond to live vaccines.
Section 5.7 Immunizations: may alter immune response to live vaccines. (Immune-suppression phrasing not verbatim, but directionally supported.)
The manufacturer provides no specific guidance on the timing of live vaccine administration after stopping Cosentyx.
In the provided excerpts, Section 5.7 provides avoidance during treatment but does not specify a post-discontinuation timing interval.
There is no specific guidance from the manufacturer or the CDC on the timing of live vaccine administration after stopping Cosentyx.
The supplied FDA label excerpts provided include guidance to avoid live vaccines during treatment but contain no timing guidance after stopping (and no CDC text is provided in the prompt).
Unsupported Statements
Live vaccines contain a weakened or attenuated form of the virus or bacteria that causes a disease.
No definition of live vaccines is present in the provided FDA label excerpts.
The CDC recommends that patients taking immunosuppressive medications, including biologics like Cosentyx, should not receive live vaccines.
No CDC recommendations are included in the provided label excerpts.
The risk of adverse reactions from live vaccines is generally low.
No statement about comparative risk or general low risk for live vaccines appears in the provided FDA label excerpts.
Some experts recommend waiting at least 4-6 weeks after stopping Cosentyx before receiving live vaccines.
No expert-recommended timing interval is included in the provided FDA label excerpts.
The timing of live vaccine administration after stopping Cosentyx should be determined on a case-by-case basis.
No case-by-case post-discontinuation timing guidance is present in the provided FDA label excerpts.
Contradictions
Low
AI Statement
Label Reference
Important Omissions
FDA label also includes other COSENTYX indications beyond the ones listed (e.g., non-radiographic axial spondyloarthritis, enthesitis-related arthritis, hidradenitis suppurativa).
Importance:
Moderate
The label excerpts provided do not include any statement about vaccine adverse reaction risk being 'generally low' (so that claim lacks label support).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
FDA label excerpts support avoidance of live vaccines in patients treated with COSENTYX and describe immune response alteration to live vaccines. Claims about post-discontinuation timing, CDC guidance, expert intervals, vaccine definitions, and general risk are not supported by the provided FDA excerpts; these reduce label alignment but do not directly contradict the core live-vaccine avoidance statement.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Several statements (CDC/expert recommendations, post-stopping timing, live vaccine definition, and 'generally low' adverse reaction risk) are not supported by the provided FDA labeling excerpts.
Suggested Improvement
Limit statements to what the provided FDA label supports: IL-17A binding/inhibition, and avoidance of live vaccines in patients treated with COSENTYX; remove or reframe unsupported timing/risk/CDC/expert claims unless additional label text is provided.